Therapy development inspired by patients


Find the latest press releases and communications on our news section.

Top-line results from Phase III ADORE study in ALS

In reference to the official press release of our pharma partner Ferrer, we regret to share that the top-line results of the phase 3 clinical study ADORE* show that the primary or key secondary endpoints were not met. In the ADORE study, our lead product TW001 (FAB122 for Ferrer), an oral version...

read more

Treeway Licensing Deal with Specialised Therapeutics

Singapore, August 28th, 2023 –Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis (ALS)¹ – the most common form of Motor Neurone...

read more

Treeway announces first patient enrolled in the Phase 2a ASURE clinical trial exploring the safety and effectiveness of oral edaravone to delay disease progression in Alzheimer’s patients

Tilburg, March 6, 2023 – Treeway, in collaboration with the Alzheimer Drug Discovery Foundation (ADDF), announces today the successful enrollment of the first patient in the Alzheimer’s Disease Study Using Oral Edaravone (ASURE), Phase 2a clinical trial. The trial will include 60 patients in...

read more